Viewing nowCombinationOlmesartan Medoxomil and Amlodipine Tablets 5/20 Milligrams
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.

MFDS item code 201406183 · Approved 2014.12.31 · Insurance code 652105400
Treatment of essential hypertension not controlled with monotherapy
This medication is used in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It effectively improves blood pressure, helping to reduce the risk of cardiovascular complications. It assists in safely managing blood pressure to maintain health.
Administer 1 tablet once daily with water, regardless of meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients in whom this medicine must not be administered in Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, and should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication's active ingredients or similar components, pregnant or breastfeeding women, and patients with severe liver disease or specific heart conditions should not take this medication. Patients with low body fluids or sodium may experience significantly lowered blood pressure upon initial use, necessitating careful monitoring of their condition, and if hypotension occurs, appropriate treatment should be sought. Patients with specific heart conditions should exercise caution due to the risk of rapid vascular expansion leading to decreases in blood pressure. Patients with heart failure or impaired kidney function should use this medication carefully following a doctor's directive, as it may affect kidney function. Patients with reduced liver function should also be cautious while taking this medication, and dosage adjustments may be necessary. Side effects such as dizziness, headache, hypotension, indigestion, edema may occur during the use of this medication, and if any unusual symptoms appear, consultation with healthcare professionals is advised. Particularly during pregnancy, this medication can have severe effects on the fetus, so it is crucial to consult a doctor if planning pregnancy or if already pregnant. Breastfeeding women should discontinue breastfeeding or stop this medication as it may be transmitted through breast milk and affect the infant. It is not recommended for use in children under 18 years of age, as the safety and efficacy in this population have not been established. Elderly patients should start with a lower dose, considering the decline in liver, kidney, or heart function and accompanying diseases, and should be monitored closely. Overdose of this medication may lead to severe hypotension and vascular dilation that could impair heart function, so immediate notification to healthcare professionals is necessary upon symptom emergence. Store this medication out of reach of children, and keep it away from moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius. This will help preserve the medication's efficacy for a long period.
White round film-coated tablet
28 tablets (14 tablets/PTP X 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Handok Co., Ltd.
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.